Sarepta Therapeutics Stock News

CAMBRIDGE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2022 tha

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the website for Route

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), el líder en medicina genética de precisión para enfermedades raras, anunció hoy que el sitio web de

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the website for Route 79, The Duchenne Scholarship Program, is officially open and accepting applications. Academic scholarships of up to $5,000 will be awarded to up to 15 individuals living with Duchenne. Additionally, for the 2022-2023 school year, the program has been expanded and Sarepta will be awarding up to 5 academic scholarships of $5,000 to siblings of individuals living with Duchenne.

Sector ETF report for FBT

Smart Beta ETF report for FBT

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at three upcoming virtual investor conferences:

Over the past 3 months, 5 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and tasked with understand

Over the past 3 months, 5 analysts have published their opinion on Sarepta Therapeutics (NASDAQ: SRPT ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company''s business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 2 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 1 0 0 2M Ago 1 0 1 0 0 3M Ago 0 1 0 0 0 These 5 analysts have an average price target of $117.6 versus the current price of Sarepta Therapeutics at $80.46, implying upside. Below is a … Full story available on Benzinga.com

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will p

Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the fourth quarter. The company also raises revenue guidance for the year. Stock down in after-market trading.

SRPT earnings call for the period ending December 31, 2021.